| Study |
No. of patients |
Onset of AF |
Endpoint |
Comparison |
Results |
| Nørgaard BL et al, 1999 [75] |
96 |
1-180 days |
Conversion to SR |
I.V. dofetilide 8 mcg/kg vs. placebo |
30.3% vs. 3.3%, P<0.006. AFl>AF, 64% vs. 24%, P<0.012 |
| Frost L et al, 1997 [76] |
98 |
1-6 days |
Conversion to SR |
I.V. dofetilide 8 mcg/kg, 4mcg/kg vs. placebo |
After 3 hr: 44% vs. 36% vs. 24%, P=insignificant. |
| Falk RH et al, 1997 [77] |
91 |
Sustained AF/AFl |
Conversion to SR |
I.V. dofetilide 8 mcg/kg, 4mcg/kg vs. placebo |
31% vs. 12.5% vs 0%. AFl>AF: (54% versus 12.5%) |
| Bianconi L et al, 2000 [78] |
150 |
2 hr-6 Mn |
|
I.V. dofetilide vs. I.V. amiodarone vs. placebo |
3 hr: 35%, 4%, and 4%, P<0.001. AFl > AF (75% vs. 22%, P=0.004) |
| Lindeboom JE et al, 2000 [79] |
|
|
|
|
|
| Singh S et al, (SAFIRE-D) 2000 [80] |
325 |
Persistent AF/AFl |
Conversion to SR. SR at 1 yr. |
dofetilide (1250mcg, 250 mcg, 500 mcg) vs. placebo |
(6.1%, 9.8%, and 29.9%) vs. 1.2%, P=0.015 and P<0.001. SR at 1 yr (0.40, 0.37, 0.58) vs. 0.25, (500 mcg vs. placebo, P < 0.001). |
| Greenbaum RE et al (EMERALD) 1998 [81] |
546 |
Persistent AF/AFl |
Conversion to SR. SR at 1 yr |
dofetilide (1250mcg, 250 mcg, 500 mcg) BID vs. Sotalol 80 BID vs. placebo |
(5.9%, 10.5%, and 29.5%) vs. 5.1% vs. 1.5%. SR at 1 yr: (30%, 45%, and 51%) vs. 38% vs. 16%. |
| Pedersen OD et al, (DIAMOND AF) 2001 [82] |
506 |
Persistent AF/AFl |
Conversion to SR. SR at 1 yr |
dofetilide vs. placebo |
59% vs. 34%. SR at 1 year: 79% vs. 42%, P<0.001. Reduced hospitalizations for worsening of heart failure (29% vs. 40%) |
| Torp-Pedersen CT et al (DIAMOND-CHF), 2000 [83] |
1518 |
NA |
SR at 1 yr |
dofetilide vs. placebo |
At 1 yr: 61% vs. 33%, P<0.001. No effect on mortality. Reduced hospitalizations for worsening of heart failure HR 0.75 (0.63-0.89). |
| DIAMOND-MI, 1997 [84] |
1510 |
NA |
SR at 1 yr |
dofetilide vs. placebo |
At 1 yr: survival 79% vs 77%. Hospitalizations for worsening of heart failure 27% for each. |
